Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NCT04126525
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
53
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer Female
Interventions
DRUG:
Pyrotinib
Sponsor
RenJi Hospital